Shots:
- TJ Bio has granted Biogen exclusive rights to felzartamab in Greater China, giving Biogen full global ownership as the drug advances through P-III trials across multiple immune-mediated diseases
- As per the deal, TJ Bio will receive $100M upfront, with ~$750M in commercial & sales milestones, plus mid-single to low-double-digit % of royalties on Greater China sales. Also, Biogen will assume responsibilities for milestone payment & royalty obligations under the prior MorphoSys licensing deal
- Biogen will lead development, manufacturing, commercialization, & post-approval efforts for felzartamab in Greater China. A BLA for MM, filed by TJ Bio in Dec 2024, is under NMPA review, with TJ Bio supplying from its Hangzhou GMP facility
Ref: PRnewswire | Image: TJ Bio & Biogen | Press Release
Related News: Biogen Collaborates with Alloy Therapeutics to Advance Antisense Therapeutics
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
